Cooper Companies (COO)
NASDAQ:COO
Want to see COO full AI Analyst Report?
COO Stock Chart & Stats
$70.06
-$0.81(-0.88%)
At close: 4:00 PM EST
$70.06
-$0.81(-0.88%)
Day’s Range― - ―
52-Week Range$58.89 - $89.83
Previous CloseN/A
Volume244.93K
Average Volume (3M)2.40M
Market Cap
$11.61B
Enterprise Value$14.32B
Total Cash (Recent Filing)$124.90M
Total Debt (Recent Filing)$2.50B
Price to Earnings (P/E)29.2
Beta0.64
Next Earnings
Jun 04, 2026EPS Estimate
1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.02
Shares Outstanding195,114,400
10 Day Avg. Volume2,594,032
30 Day Avg. Volume2,402,381
Financial Highlights & Ratios
PEG Ratio-8.16
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue3.45
Enterprise Value/Gross Profit5.37
Enterprise Value/Ebitda14.88
Forecast
1Y Price Target
$86.75Price Target Upside23.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)4.62
Revenue Forecast (FY)$4.32B
Bulls Say, Bears Say
Bulls Say
Earnings And Cash FlowStronger-than-expected margins and free cash flow led management to raise free cash flow guidance, improving the company's financial flexibility and supporting potential shareholder returns.
Product Launches And SupplyImproved MyDay supply and new silicone hydrogel lens launches expand the addressable market and enable private-label agreements that can accelerate contact-lens revenue growth.
Strategic Review And Shareholder ActionsBoard-led strategic review combined with governance changes and a renewed focus on total shareholder return raises the likelihood of value-unlocking actions such as a separation or targeted share repurchases.
Bears Say
Competitive Pressure In ContraceptivesNew non-hormonal intrauterine devices and rival contraceptive launches create tangible competitive pressure on Paragard and could reduce volumes in specific patient segments.
Contact Lens And Myopia CompetitionMuted contact-lens volume growth and competitive threats from spectacles and rival products add uncertainty to MiSight's market share and could cap upside for the contact-lens business.
Japan Market HeadwindsIntense price competition and an older hydrogel product mix in Japan weighed on regional sales and could delay recovery until newer products gain uptake.
Cooper Co News
COO FAQ
What was Cooper Companies’s price range in the past 12 months?
Cooper Companies lowest stock price was $58.89 and its highest was $89.83 in the past 12 months.
What is Cooper Companies’s market cap?
Cooper Companies’s market cap is $11.61B.
When is Cooper Companies’s upcoming earnings report date?
Cooper Companies’s upcoming earnings report date is Jun 04, 2026 which is today.
How were Cooper Companies’s earnings last quarter?
Currently, no data Available
Is Cooper Companies overvalued?
According to Wall Street analysts Cooper Companies’s price is currently Undervalued.
Does Cooper Companies pay dividends?
Cooper Companies pays a Semiannually dividend of $0.007 which represents an annual dividend yield of N/A. See more information on Cooper Companies dividends here
What is Cooper Companies’s EPS estimate?
Cooper Companies’s EPS estimate is 1.1.
How many shares outstanding does Cooper Companies have?
Cooper Companies has 195,114,400 shares outstanding.
What happened to Cooper Companies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cooper Companies?
Currently, no hedge funds are holding shares in COO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$86.75 (23.82% Upside)
$86.75 (23.82% Upside)
Blogger Sentiment
Bullish
COO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 5.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 27.9%
Last 30 Days ▲ 21.9%
Last 30 Days ▲ 21.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.20%
12-Months-Change
Fundamentals
Return on Equity
4.83%
Trailing 12-Months
Asset Growth
1.65%
Trailing 12-Months
Company Description
Cooper Companies
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
COO Company Deck
COO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational execution with revenue growth, a substantial EPS beat (+20%), robust free cash flow and raised guidance for earnings and FCF. Product momentum (MyDay and MiSight), continued market share gains, and realized synergies from reorganization and AI/IT investments are clear positives. Key challenges include Asia Pacific (notably Japan) softness that modestly depressed quarterly organic growth, some regional fertility and Paragard pressures, tariff/FX headwinds and isolated legal costs. Management expects these headwinds to be temporary (APAC recovery in Q3) and is allocating savings to growth initiatives while continuing buybacks and debt reduction.View all COO earnings summariesCOO Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
COO Stock 12 Month Forecast
Average Price Target
$86.75
▲(23.82% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
36.80% Mutual Funds
23.12% Other Institutional Investors
12.80% Public Companies and
Individual Investors